OHI A.I CyberSecurity Scoring
26/11/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Organovo Holdings, Inc. in 2026.
No incidents recorded for Organovo Holdings, Inc. in 2026.
No incidents recorded for Organovo Holdings, Inc. in 2026.
Biotechnology Research
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
Latest updates, reports, and threat intel affecting the global network.
(Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in ...
The announcement by Organovo regarding its public offering of $5.25 million includes both the issuance of new shares and common warrants with an ...
Organovo Holdings (Nasdaq: ONVO) has announced its transformation into VivoSim Labs, Inc., marking a strategic evolution of its 3D ...
(Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in ...
Organovo now expects to establish an operating cadence that leverages existing capital at a rate sufficient to push through the end of FY2026.
Welcome to our dedicated page for Organovo Holding news (Ticker: ONVO), a resource for investors and traders seeking the latest updates and insights on ...
FOSSBilling is a free, open-source billing and client management system. In versions 0.5.6 through 0.7.2, when a `ClientPasswordReset` record already exists for a client (from a previous unexpired reset request), subsequent calls to the `reset_password` guest API endpoint reuse the existing token instead of generating a new one. The 15-minute validity window is anchored to the first request's `created_at` timestamp, not the time of the most recent email. An attacker who obtained the original reset link remains able to use it even after the victim requests a new reset, because the original token is never invalidated or rotated. Version 0.8.0 patches the issue. Some workarounds are available. Configure a reverse proxy (e.g., Nginx, Apache, Cloudflare) to apply per-IP rate limiting to the `/client/reset-password` endpoint to minimize the window of opportunity, and/or manually clear expired `client_password_reset` records from the database after a client reports a suspected compromise.
FOSSBilling is a free, open-source billing and client management system. Versions prior to 0.8.0 allow a low-privileged staff account to grant arbitrary module permissions to itself through the admin API, resulting in persistent privilege escalation. A staff user that only has `staff.create_and_edit_staff` can call `/api/admin/staff/permissions_update` targeting their own account and write any permission structure, bypassing the intended role-based access control boundary. Version 0.8.0 patches the issue. Some workarounds are available. Restrict the `staff.create_and_edit_staff` permission to only highly trusted staff members and/or use a reverse proxy or WAF to restrict access to `/api/admin/staff/permissions_update` to specific trusted roles.
FOSSBilling is a free, open-source billing and client management system. Versions 0.5.3 through 0.7.2 allow authenticated clients to both read and reset API key service secrets for orders that are no longer in an `active` state (e.g., `suspended`, `canceled`). The root cause is missing order-state validation in two client API endpoints, despite an `isActive()` helper already existing in the `Serviceapikey` module and the frontend UI correctly gating access on `order.status == 'active'`. Version 0.8.0 contains a fix. Some workarounds are available. If the `Serviceapikey` module is not needed, uninstall it to remove the affected endpoints. One may also use a reverse proxy or WAF to restrict access to `/api/client/order/service` and `/api/client/serviceapikey/reset` based on application-level order-state logic.
FOSSBilling is a free, open-source billing and client management system. Versions prior to 0.8.0 allow low-privileged staff accounts to perform unauthorized actions via admin API endpoints. The root cause is a combination of the `can_always_access` module flag (which grants all staff access to certain modules) and insufficient permission checks or unsafe parameter handling on individual endpoints. Version 0.8.0 contains a fix. Some workarounds are available. Restrict staff accounts to only those who need access to sensitive settings and/or use a reverse proxy or WAF to restrict access to the affected endpoints to trusted IP addresses or higher-privilege roles.
FOSSBilling is a free, open-source billing and client management system. In versions 0.5.6 through 0.7.2, when the "Require Email Confirmation" setting is enabled, a logged-in client with an unverified email address (`email_approved = 0`) can access all client-area pages (e.g. `/client/balance`, `/client/order/list`, `/client/invoice`) and read real account data, including wallet balances and transaction history. The API-side enforcement correctly restricts unverified clients to only profile-related endpoints, but the page-side enforcement is overly permissive, allowing any request whose path starts with `/client`. Version 0.8.0 contains a fix. No known workarounds that don't involve modifying the source code are available.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.